XtalPi, a provider of AI-powered drug discovery solutions, and Parthenon Therapeutics, a clinical-stage biotechnology company dedicated to reprogramming the tumor microenvironment, announced a collaboration to discover novel therapeutic antibodies for the treatment of solid tumors.
Under this agreement, XtalPi will grant Parthenon Therapeutics access to its proprietary XupremAb™ antibody discovery platform, which is a collection of solutions that leverage AI and wet lab techniques to deliver therapeutic antibody candidates with superior efficacy and developability profiles. Parthenon Therapeutics and XtalPi will utilize multiple approaches in the XupremAb™ platform for deeper interrogation of the immune repertoire and generating a large, consolidated dataset, which will be further mined by XtalPi's proprietary algorithms for exceptional candidates.
"We are excited to work with Parthenon Therapeutics on this pioneering project. Their strong innovation in tumor barrier disruption and deep understanding of the target, coupled with our broadly validated AI-powered antibody discovery platform, forms a solid foundation for the development of next-generation cancer therapeutics," said Yi Li, VP of Antibody Discovery, XtalPi.
"We are very pleased to collaborate with XtalPi to leverage their cutting-edge proprietary platform to deeply mine the immune repertoire to discover novel state-of-the-art antibody therapeutics. Combined with Parthenon's vast expertise in biotherapeutic drug discovery and unique insights into the tumor microenvironment and the mechanisms underlying immune exclusion, we look forward to developing transformative therapies for cancer patients," said Tom McCaughtry, VP – Head of Research, Parthenon Therapeutics.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!